ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)

London-based AI drug discovery startup Boltz raised $110 million in a Series A round led by Bessemer Venture Partners. New investors include Greycroft, F-Prime Capital, Hummingbird, Benchling, and Nvidia. The startup employs 40 researchers and collaborates with Pfizer, GSK, Takeda, and Bristol Myers Squibb to speed up drug discovery using open-source AI models.
Tracked by ByteBrief